IL-6 blockade for COVID-19: a global scientific call to arms

Lancet Respir Med. 2021 May;9(5):438-440. doi: 10.1016/S2213-2600(21)00127-2. Epub 2021 Mar 4.

Authors

Srinivas Murthy¹, Todd C Lee²

Affiliations

¹ Department of Pediatrics, University of British Columbia, Vancouver, BC V6H 3V4, Canada. Electronic address: srinivas.murthy@cw.bc.ca.
² Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montréal, QC, Canada; Division of Infectious Diseases, Department of Medicine, McGill University, Montréal, QC, Canada.

No abstract available

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
COVID-19 Drug Treatment*
Humans
Interleukin-6 / antagonists & inhibitors*
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
Interleukin-6
tocilizumab
sarilumab